Cross‐Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine | Zendy

Takeshi Ichinohe | Zendy; Shinichi Tamura | Zendy; Akira Kawaguchi | Zendy; Ai Ninomiya | Zendy; Masaki Imai | Zendy; Shigeyuki Itamura | Zendy; Takato Odagiri | Zendy; Masato Tashiro | Zendy; Hidehiro Takahashi | Zendy; Hirofumi Sawa | Zendy; William M. Mitchell | Zendy; David R. Strayer | Zendy; William A. Carter | Zendy; Joe Chiba | Zendy; Takeshi Kurata | Zendy; Tetsutaro Sata | Zendy; Hideki Hasegawa | Zendy

Open Access

Cross‐Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine

Author(s) -

Takeshi Ichinohe,

Shinichi Tamura,

Akira Kawaguchi,

Ai Ninomiya,

Masaki Imai,

Shigeyuki Itamura,

Takato Odagiri,

Masato Tashiro,

Hidehiro Takahashi,

Hirofumi Sawa,

William M. Mitchell,

David R. Strayer,

William A. Carter,

Joe Chiba,

Takeshi Kurata,

Tetsutaro Sata,

Hideki Hasegawa

Publication year - 2007

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/521304

Subject(s) - virology , nasal administration , inoculation , influenza a virus subtype h5n1 , virus , influenza vaccine , orthomyxoviridae , influenza a virus , microbiology and biotechnology , medicine , biology , immunology

Avian H5N1 influenza A virus is an emerging pathogen with the potential to cause substantial human morbidity and mortality. We evaluated the ability of currently licensed seasonal influenza vaccine to confer cross-protection against highly pathogenic H5N1 influenza virus in mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research